3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
3
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
10
Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
SCLC,Extensive Stage
1
Rare Tumor
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Laryngeal Diseases
1
Hemangiosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
55
Carboplatin
33
Paclitaxel
24
Cyclophosphamide
23
Capecitabine
18
sacituzumab govitecan
16
130-nm albumin-bound paclitaxel
15
Specimen Handling
14
toripalimab
11
Drug Therapy
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
Bevacizumab
10
Taxes
9
Epirubicin
9
durvalumab
8
Albumin-Bound Paclitaxel
8
olaparib
7
camrelizumab
7
Gemcitabine
7
Doxorubicin
7
Docetaxel
7
fludarabine
6
famitinib
5
Nivolumab
5
Injections
5
atezolizumab
4
abemaciclib
4
Trastuzumab
4
Standard of Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Breast Neoplasms
×
niraparib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled